Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxLSE:VRCI Beneish M-Score is 22.89 as of Jul. 23, 2026, which is 109% above its 10-year median of 10.94. The stock has 3 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Verici Dx ranks worse than 99.48% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score 22.89 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for Verici Dx's Beneish M-Score or its related term are showing as below:
LSE:VRCI'
s Beneish M-Score Range Over the Past 10 Years
Min: -1.01 Med: 10.94 Max: 22.89
Current: 22.89
During the past 6 years, the highest Beneish M-Score of Verici Dx was 22.89. The lowest was -1.01. And the median was 10.94.
Verici Dx Beneish M-Score Related Terms
Verici Dx Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Verici Dx's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VRCI vs TMO, DHR, IDXX: Beneish M-Score Comparison
For the Diagnostics & Research subindustry, Verici Dx's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx Beneish M-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Verici Dx's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Verici Dx for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 27.4035
+
0.528 * 1.291
+
0.404 * 0.9802
+
0.892 * 1.0363
+
0.115 * 0.8329
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.9438
+
4.679 * 0.167763
-
0.327 * 0.6082
=
22.89
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(0.554 / (0.554 + 0.679))
/
(0.424 / (0.424 + 0.362))
=
0.449311
/
0.53944
=
0.8329
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-5.179 - 0
-
-6.174)
/
5.931
=
0.167763
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Verici Dx has a M-score of 22.89 signals that the company is likely to be a manipulator.
Verici Dx (LSE:VRCI) has a Beneish M-Score of 22.89 as of Jul. 23, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Verici Dx and its competitors. This is 109% above median its historical median of 10.94. According to the industry distribution chart, Verici Dx ranks #193 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 99.5%.
Is Verici Dx's Beneish M-Score too high?
Verici Dx's current Beneish M-Score of 22.89 is 109% above median its 10-year median of 10.94. Based on the distribution chart, Verici Dx ranks #193 out of 194 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Verici Dx's Beneish M-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #193 out of 194 companies for Beneish M-Score. This places Verici Dx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Verici Dx and its competitors. Verici Dx's current Beneish M-Score is 22.89, which is 109% above median its own 10-year median of 10.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current Beneish M-Score of 22.89. The current Beneish M-Score is 22.89, which is 109% above median its 10-year median of 10.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current Beneish M-Score is 22.89 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VRCI has been successfully added to your 
